[1] |
VAN HERPT TTW, TIMMERMANS SAMEG, VAN MOOK WNKA, et al. Postsurgical thrombotic microangiopathy and deregulated complement[J]. J Clin Med, 2022, 11(9): 2501. DOI: 10.3390/jcm11092501.
|
[2] |
ABOU-ISMAIL MY, KAPOOR S, CITLA SRIDHAR D, et al. Thrombotic microangiopathies: an illustrated review[J]. Res Pract Thromb Haemost, 2022, 6(3): e12708. DOI: 10.1002/rth2.12708.
|
[3] |
ÁVILA A, GAVELA E, SANCHO A. Thrombotic microangiopathy after kidney transplantation: an underdiagnosed and potentially reversible entity[J]. Front Med (Lausanne), 2021, 8: 642864. DOI: 10.3389/fmed.2021.642864.
|
[4] |
BROCKLEBANK V, WOOD KM, KAVANAGH D. Thrombotic microangiopathy and the kidney[J]. Clin J Am Soc Nephrol, 2018, 13(2): 300-317. DOI: 10.2215/CJN.00620117.
|
[5] |
VANIKAR AV, KANODIA KV, SUTHAR KS, et al. Thrombotic microangiopathy in a renal allograft: single-center five-year experience[J]. Saudi J Kidney Dis Transpl, 2020, 31(6): 1331-1343. DOI: 10.4103/1319-2442.308342.
|
[6] |
SAIKUMAR DORADLA LP, LAL H, KAUL A, et al. Clinical profile and outcomes of de novo posttransplant thrombotic microangiopathy[J]. Saudi J Kidney Dis Transpl, 2020, 31(1): 160-168. DOI: 10.4103/1319-2442.279936.
|
[7] |
MULGAONKAR S, KAUFMAN DB. Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients[J]. Clin Transplant, 2014, 28(11): 1209-1224. DOI: 10.1111/ctr.12453.
|
[8] |
NAGAO RJ, MARCU R, SHIN YJ, et al. Cyclosporine induces fenestra-associated injury in human renal microvessels in vitro[J]. ACS Biomater Sci Eng, 2022, 8(1): 196-207. DOI: 10.1021/acsbiomaterials.1c00986.
|
[9] |
WU Q, WANG X, NEPOVIMOVA E, et al. Mechanism of cyclosporine A nephrotoxicity: oxidative stress, autophagy, and signaling[J]. Food Chem Toxicol, 2018, 118: 889-907. DOI: 10.1016/j.fct.2018.06.054.
|
[10] |
VERPOOTEN GA, COOLS FJ, VAN DER PLANKEN MG, et al. Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients[J]. Nephrol Dial Transplant, 1996, 11(2): 347-351. DOI: 10.1093/oxfordjournals.ndt.a027265.
|
[11] |
RENNER B, KLAWITTER J, GOLDBERG R, et al. Cyclosporine induces endothelial cell release of complement-activating microparticles[J]. J Am Soc Nephrol, 2013, 24(11): 1849-1862. DOI: 10.1681/ASN.2012111064.
|
[12] |
NAVA F, CAPPELLI G, MORI G, et al. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation[J]. Transplant Proc, 2014, 46(7): 2263-2268. DOI: 10.1016/j.transproceed.2014.07.062.
|
[13] |
KEIR LS, FIRTH R, APONIK L, et al. VEGF regulates local inhibitory complement proteins in the eye and kidney[J]. J Clin Invest, 2017, 127(1): 199-214. DOI: 10.1172/JCI86418.
|
[14] |
AL-NOURI ZL, REESE JA, TERRELL DR, et al. Drug-induced thrombotic microangiopathy: a systematic review of published reports[J]. Blood, 2015, 125(4): 616-618. DOI: 10.1182/blood-2014-11-611335.
|
[15] |
BAID-AGRAWAL S, FARRIS AB 3RD, PASCUAL M, et al. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy[J]. Kidney Int, 2011, 80(8): 879-885. DOI: 10.1038/ki.2011.194.
|
[16] |
RANE S, NADA R, MINZ M, et al. Spectrum of cytomegalovirus-induced renal pathology in renal allograft recipients[J]. Transplant Proc, 2012, 44(3): 713-716. DOI: 10.1016/j.transproceed.2011.11.052.
|
[17] |
JAVA A, EDWARDS A, ROSSI A, et al. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature[J]. Transpl Int, 2015, 28(9): 1121-1125. DOI: 10.1111/tri.12582.
|
[18] |
MITSUIKI N, TAMANUKI K, SEI K, et al. Severe neonatal CMV infection complicated with thrombotic microangiopathy successfully treated with ganciclovir[J]. J Infect Chemother, 2017, 23(2): 107-110. DOI: 10.1016/j.jiac.2016.08.007.
|
[19] |
THOREAU B, VON TOKARSKI F, BAUVOIS A, et al. Infection in patients with suspected thrombotic microangiopathy based on clinical presentation[J]. Clin J Am Soc Nephrol, 2021, 16(9): 1355-1364. DOI: 10.2215/CJN.17511120.
|
[20] |
ARDALAN MR, SHOJA MM, TUBBS RS, et al. Parvovirus B19 microepidemic in renal transplant recipients with thrombotic microangiopathy and allograft vasculitis[J]. Exp Clin Transplant, 2008, 6(2): 137-143.
|
[21] |
STEFFEN CJ, KOCH N, ECKARDT KU, et al. Hemophagocytic lymphohistiocytosis and thrombotic microangiopathy after parvovirus B19 infection and renal transplantation: a case report[J]. BMC Nephrol, 2021, 22(1): 337. DOI: 10.1186/s12882-021-02538-0.
|
[22] |
WU K, BUDDE K, SCHMIDT D, et al. The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy[J]. Clin Transplant, 2016, 30(2): 105-117. DOI: 10.1111/ctr.12645.
|
[23] |
FARKASH EA, COLVIN RB. Diagnostic challenges in chronic antibody-mediated rejection[J]. Nat Rev Nephrol, 2012, 8(5): 255-257. DOI: 10.1038/nrneph.2012.61.
|
[24] |
中华医学会器官移植学分会. 肾移植排斥反应临床诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(5): 505-512. DOI: 10.3969/j.issn.1674-7445.2019.05.008.Branch of Organ Transplantation of Chinese Medical Association. Technical specification for the diagnosis and treatment on rejection of renal transplantation (2019 edition)[J]. Organ Transplant, 2019, 10(5): 505-512. DOI: 10.3969/j.issn.1674-7445.2019.05.008.
|
[25] |
LOUPY A, HAAS M, ROUFOSSE C, et al. The Banff 2019 kidney meeting report (Ⅰ): updates on and clarification of criteria for T cell- and antibody-mediated rejection[J]. Am J Transplant, 2020, 20(9): 2318-2331. DOI: 10.1111/ajt.15898.
|
[26] |
BLASCO M, GUILLÉN-OLMOS E, DIAZ-RICART M, et al. Complement mediated endothelial damage in thrombotic microangiopathies[J]. Front Med (Lausanne), 2022, 9: 811504. DOI: 10.3389/fmed.2022.811504.
|
[27] |
NORIS M, REMUZZI G. Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?[J]. Kidney Int, 2019, 96(1): 13-15. DOI: 10.1016/j.kint.2019.02.038.
|
[28] |
TAYLOR CM, MACHIN S, WIGMORE SJ, et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom[J]. Br J Haematol, 2010, 148(1): 37-47. DOI: 10.1111/j.1365-2141.2009.07916.x.
|
[29] |
LEVI C, FRÉMEAUX-BACCHI V, ZUBER J, et al. Midterm outcomes of 12 renal transplant recipients treated with eculizumab to prevent atypical hemolytic syndrome recurrence[J]. Transplantation, 2017, 101(12): 2924-2930. DOI: 10.1097/TP.0000000000001909.
|
[30] |
PRÉVEL R, DELMAS Y, GUILLOTIN V, et al. Complement blockade is a promising therapeutic approach in a subset of critically ill adult patients with complement-mediated hemolytic uremic syndromes[J]. J Clin Med, 2022, 11(3): 790. DOI: 10.3390/jcm11030790.
|
[31] |
PALOMO M, BLASCO M, MOLINA P, et al. Complement activation and thrombotic microangiopathies[J]. Clin J Am Soc Nephrol, 2019, 14(12): 1719-1732. DOI: 10.2215/CJN.05830519.
|
[32] |
BLASCO M, GUILLÉN E, QUINTANA LF, et al. Thrombotic microangiopathies assessment: mind the complement[J]. Clin Kidney J, 2020, 14(4): 1055-1066. DOI: 10.1093/ckj/sfaa195.
|
[33] |
GARG N, RENNKE HG, PAVLAKIS M, et al. De novo thrombotic microangiopathy after kidney transplantation[J]. Transplant Rev (Orlando), 2018, 32(1): 58-68. DOI: 10.1016/j.trre.2017.10.001.
|
[34] |
ZHENG L, ZHANG D, CAO W, et al. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy[J]. Blood, 2019, 134(13): 1095-1105. DOI: 10.1182/blood.2019001040.
|
[35] |
BUDDE K, PRASHAR R, HALLER H, et al. Conversion from calcineurin inhibitor to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial[J]. J Am Soc Nephrol, 2021, 32(12): 3252-3264. DOI: 10.1681/ASN.2021050628.
|
[36] |
ASHMAN N, CHAPAGAIN A, DOBBIE H, et al. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy[J]. Am J Transplant, 2009, 9(2): 424-427. DOI: 10.1111/j.1600-6143.2008.02482.x.
|
[37] |
JORDAN SC, AMMERMAN N, CHOI J, et al. The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection[J]. Am J Transplant, 2020, 20 (Suppl 4): 42-56. DOI: 10.1111/ajt.15913.
|
[38] |
SCHWOTZER N, PAGANETTI G, BARCHI M, et al. Upfront use of eculizumab to treat early acute antibody-mediated rejection after kidney allotransplantation and relevance for xenotransplantation[J]. Xenotransplantation, 2020, 27(4): e12630. DOI: 10.1111/xen.12630.
|
[39] |
MEEHAN SM, KREMER J, ALI FN, et al. Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies[J]. Clin J Am Soc Nephrol, 2011, 6(2): 395-403. DOI: 10.2215/CJN.05870710.
|
[40] |
ÖZLÜ SG, GÜLHAN B, AYDOĞ Ö, et al. Could plasma based therapies still be considered in selected cases with atypical hemolytic uremic syndrome?[J]. Turk J Pediatr, 2021, 63(6): 986-993. DOI: 10.24953/turkjped.2021.06.006.
|
[41] |
MITTAL A, DIJOO M, AGGARWAL S, et al. Rituximab to abbreviate plasma exchange in anti-CFH (complement factor H) antibody mediated atypical HUS[J]. Iran J Kidney Dis, 2019, 13(2): 134-138.
|
[42] |
AIGNER C, BÖHMIG GA, ESKANDARY F, et al. Preemptive plasma therapy prevents atypical hemolytic uremic syndrome relapse in kidney transplant recipients[J]. Eur J Intern Med, 2020, 73: 51-58. DOI: 10.1016/j.ejim.2019.11.007.
|
[43] |
ZUBER J, LE QUINTREC M, SBERRO-SOUSSAN R, et al. New insights into postrenal transplant hemolytic uremic syndrome[J]. Nat Rev Nephrol, 2011, 7(1): 23-35. DOI: 10.1038/nrneph.2010.155.
|
[44] |
GONZALEZ SUAREZ ML, THONGPRAYOON C, MAO MA, et al. Outcomes of kidney transplant patients with atypical hemolytic uremic syndrome treated with eculizumab: a systematic review and meta-analysis[J]. J Clin Med, 2019, 8(7): 919. DOI: 10.3390/jcm8070919.
|
[45] |
LOIRAT C, FAKHOURI F, ARICETA G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children[J]. Pediatr Nephrol, 2016, 31(1): 15-39. DOI: 10.1007/s00467-015-3076-8.
|
[46] |
ÖZÇAKAR ZB, OZALTIN F, GÜLHAN B, et al. Transplantation in pediatric aHUS within the era of eculizumab therapy[J]. Pediatr Transplant, 2021, 25(3): e13914. DOI: 10.1111/petr.13914.
|
[47] |
SELLIER-LECLERC AL, FREMEAUX-BACCHI V, DRAGON-DUREY MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome[J]. J Am Soc Nephrol, 2007, 18(8): 2392-2400. DOI: 10.1681/ASN.2006080811.
|
[48] |
JALANKO H, PELTONEN S, KOSKINEN A, et al. Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H[J]. Am J Transplant, 2008, 8(1): 216-221. DOI: 10.1111/j.1600-6143.2007.02029.x.
|
[49] |
KIM S, PARK E, MIN SI, et al. Kidney transplantation in patients with atypical hemolytic uremic syndrome due to complement factor H deficiency: impact of liver transplantation[J]. J Korean Med Sci, 2018, 33(1): e4. DOI: 10.3346/jkms.2018.33.e4.
|
[50] |
COPPO R, BONAUDO R, PERUZZI RL, et al. Liver transplantation for aHUS: still needed in the eculizumab era?[J]. Pediatr Nephrol, 2016, 31(5): 759-768. DOI: 10.1007/s00467-015-3278-0.
|